Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$28.47 USD
-0.13 (-0.45%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $28.45 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MYGN 28.47 -0.13(-0.45%)
Will MYGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYGN
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Continue to Retain MYGN Stock in Your Portfolio?
Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound?
New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues
Other News for MYGN
Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
Myriad Genetics to share new data on genetic testing advancements
Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN)
Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN)
Myriad Genetics Inc (MYGN) Stock Price Down 4.33% on Sep 11